Pre-Clinical Assessment of Novel Multivalent MSP3 Malaria Vaccine Constructs by Bang, Gilles et al.
Pre-Clinical Assessment of Novel Multivalent MSP3
Malaria Vaccine Constructs
Gilles Bang
., Eric Prieur
., Christian Roussilhon, Pierre Druilhe*
Malaria Vaccine Development Laboratory, Institut Pasteur, and Vac4all initiative, Paris, France
Abstract
Background: MSP3 has been shown to induce protection against malaria in African children. The characterization of a family
of Plasmodium falciparum merozoite surface protein 3 (MSP3) antigens sharing a similar structural organization,
simultaneously expressed on the merozoite surface and targeted by a cross-reactive network of protective antibodies, is
intriguing and offers new perspectives for the development of subunit vaccines against malaria.
Methods: Eight recombinant polyproteins containing carefully selected regions of this family covalently linked in different
combinations were all efficiently produced in Escherichia coli. The polyproteins consisted of one monovalent, one bivalent,
one trivalent, two tetravalents, one hexavalent construct, and two tetravalents incorporating coiled-coil repeats regions
from LSA3 and p27 vaccine candidates.
Results: All eight polyproteins induced a strong and homogeneous antibody response in mice of three distinct genotypes,
with a dominance of cytophilic IgG subclasses, lasting up to six months after the last immunization. Vaccine-induced
antibodies exerted a strong monocyte-mediated in vitro inhibition of P. falciparum growth. Naturally acquired antibodies
from individuals living in an endemic area of Senegal recognized the polyproteins with a reactivity mainly constituted of
cytophilic IgG subclasses.
Conclusions: Combination of genetically conserved and antigenically related MSP3 proteins provides promising subunit
vaccine constructs, with improved features as compared to the first generation construct employed in clinical trials (MSP3-
LSP). These multivalent MSP3 vaccine constructs expand the epitope display of MSP3 family proteins, and lead to the
efficient induction of a wider range of antibody subclasses, even in genetically different mice. These findings are promising
for future immunization of genetically diverse human populations.
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Introduction
Malaria caused by Plasmodium falciparum (P. falciparum) is one of
infectious diseases with the greatest impact on worldwide public
health with morbidity figures of 300–500 million and mortality
reaching nearly one million per year. Control of the disease has
become difficult with increasing drug-resistant forms of parasites,
resistance of Anopheles mosquito vectors to insecticides and global
warming. A safe and affordable malaria vaccine would offer the
most cost-effective tool to curb this situation.
Several vaccines aimed at rolling back malaria are currently at
various stages of development. Among blood stages proteins
considered as vaccine candidates, antigens expressed by merozo-
ites have emerged as the most promising vaccine candidates. The
merozoite surface protein 3 (MSP3.1) was selected based on
immuno-clinical analysis of natural P. falciparum and human host
interactions [1]. The value of MSP3.1 as a vaccine candidate was
reinforced when it was found that the C-terminus domain was
highly conserved among various P. falciparum field isolates from
Africa and Asia [2,3]. A 69 amino acids (aa) region in the C-
terminus region displayed promising features for the development
of a subunit vaccine in several studies involving malaria exposed
individuals and malaria naı ¨ve adults enrolled in a phase I trial
[4,5,6,7,8,9]. Results showed that a MSP3-long synthetic peptide
(MSP3-LSP) vaccine formulation combining conserved epitopes
from MSP3.1-CT elicited high humoral and cellular immune
responses in human volunteers. The B-cell response was primarily
constituted of cytophilic IgG subclasses (IgG1 & IgG3) which were
effective at achieving parasite killing in vitro in cooperation with
blood monocytes, and which were also found associated with
protection against malaria attacks in individuals from endemic
areas [10]. Recent results moreover show that this construct can
induce protection against clinical malaria in young African
children [9].
We have observed that msp3 belongs to a multigene family with
unusual features, which distinguish it from all other P. falciparum
multigene families such as var and rifin. The new multigene family
located on chromosome 10, encodes for six merozoite surface
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terminal regions. They are simultaneously transcribed and
expressed on the merozoite surface. They include regions with
sequence homologies flanked by regions that markedly differ from
one family member to the other. Their full sequence conservation
among distinct isolates is striking and most unusual [11].
Antigenicity analysis of this MSP3 multigene family using 6 C-
term recombinant proteins and 36 peptides derived from them (i.e.
6 epitopes covering regions ‘‘a’’ to ‘‘f’’ from each C-T) showed that
all peptides were antigenic, with a distinct IgG isotype pattern for
each, though with an overall predominance of the IgG3 subclass.
Human antibodies affinity-purified upon each of the 36 peptides
exerted an anti parasitic activity through an antibody-dependent
cell inhibition (ADCI) in cooperation with blood monocytes.
Region covering epitopes ‘‘b’’ to ‘‘d’’ displays the highest
homology among the six proteins and generates a broad network
of antibodies cross-reactive with the remaining proteins with
various avidities [12]. In addition, within non-homologous regions,
sequence divergences from one gene to the other, were thought to
be related to T-helper function, and this was documented in
MSP3.1, each sequence being potentially better fitted to a given
MHC class-II subset. The genetic conservation of this diversity
would possibly provide improved T-cell help in individuals with
diverse MHC class-II genetic background [13]. Conversely,
immunogenicity studies indicated that certain regions are involved
in the regulation of the intensity of immune responses: i.e.
removing the ‘‘e–f’’ region from MSP3.1 resulted in an increase by
two orders of magnitude of antibodies to the ADCI-relevant ‘‘b–
d’’ region [13]. We have argued previously that this conservation
of homologous and divergent regions could contribute to generate
a wider range of diversity in affinity, avidity and fine-specificity in
the antibody repertoire [11]. This might result in reactivity to a
wide range of original and related epitopes and lead to greater
efficacy of in vitro growth inhibition of parasite in the ADCI.
At the origin of the present work is the hypothesis that, by
increasing the number of protective epitopes delivered in a vaccine
formulation, more balanced and better-targeted responses would
be generated in a larger range of immuno-genetically diverse
population. Therefore, we designed eight new and different
chimerical vaccine constructions, by combining homologous and
non-homologous sequences derived from each of the six msp3
genes. The design of each vaccine construct was based on
information gathered previously about: i. Structural organisation,
sequence and conservation of each family member [11]; ii.
Detailed antigenicity data gathered in endemic area populations
using 36 peptides derived from the 6 proteins [12] and iii.
Immunogenicity data obtained in mice [13].
In the present study we evaluated the immunological properties
of these eight polyproteins with regard to three main criteria: a)
Immunogenicity in 3 mouse strains; b) Antigenicity in sera from
endemic area individuals (Ndiop, Senegal); c) Ability of vaccine-
induced antibodies to recognize native parasite antigens and exert
in vitro an anti parasitic activity in ADCI. This preclinical approach
was aimed at selecting the constructions recognized by functional
antibodies naturally produced by malaria-exposed human beings
and inducing broad, diverse antibody responses, consisting of
antibodies efficient in MN-dependant parasite killing.
Materials and Methods
Ethics Statement
Procedures and experiments involving mice were approved by
InstitutPasteurSafetyCommitteeandperformedinaccordancewith
French legislation in general and in particular with Institut Pasteur
Ethical Committee guidelines for animal handling warranted by the
Approval Number A7515-27. Human blood samples from healthy
malaria naive volunteers were sampled at the Etablissement Franc ¸ais
du Sang (EFS, Paris) and used in accordance with French legislation
in general and in particular with a convention between Institut
Pasteur and EFS as licensed by Approval ID HS2003-3251.
Parasites
Asexual blood stage parasites of Plasmodium falciparum (3D7 clone)
were cultured in complete medium (CM) composed of RPMI 1640
with L-Glutamine (Invitrogen) supplemented with 5 mg Hypoxan-
thine, 35 mM HEPES, 23 mM NaHCO3 and 0.5% Albumax I
(Invitrogen) in the presence of AB
+ erythrocytes. Cultures were
maintained at 37uC in a humidified 5% CO2 incubator. When
required, ring stage or schizont stage parasites were enriched
respectively either by 5% sorbitol treatment (Acros Organics) or by
flotation on 1% porcine skin gelatin type A (Sigma-Aldrich).
Antigens
The recombinant antigens used in this study corresponded to the
C-terminal part of the P. falciparum (strain 3D7) MSP3 proteins
(MSP3-CT); (MSP3.1167–354; PlasmoDB ID: PF10_0345,
MSP3.2161–371; PlasmoDB ID: PF10_0346, MSP3.3228–424; Plas-
moDB ID: PF10_0347, MSP3.4508–697; PlasmoDB ID: PF10_0348,
MSP3.7214–405; PlasmoDB ID: PF10_0352, MSP3.8537–762; Plas-
moDB ID: PF10_0355). The recombinant antigens corresponding
to LSA1 (P. falciparum T9/96 clone, GenBank ID: Z30_320.1) and
LSA3-GST729 (P. falciparum T9/96 clone, GenBank ID: AJ007011)
were produced as previously described [14,15]. The p27 peptide
(PlasmoDB ID: PFF0165c) corresponding to amino acids AA845–871
from a protein targeted by the antibody-dependent parasite growth
inhibition mechanism (ADCI) was a gift from Pr. Giampietro
Corradin (University of Lausanne, Switzerland) [16].
MSP3-derived polyprotein (PP) immunogens
In the following, MSP3-1 to MSP3-6 refers to the 6 proteins
belonging to the MSP3 multigene family, whereas the polyproteins
PP-1 to PP-8 refer to the constructs assembling different fragments
from the MSP3 proteins (Figure 1). They are called ‘‘PP’’ to make it
easier for the reading. Nucleic acid sequences coding for the MSP3
polyproteins (PPs) were chemically synthesized (GenScript). The
MSP3 aminoacid sequencescovalently linkedinthe 8PPconstructs
(Figure 1) were selected for their antigenic and immunological pro-
perties as well as for their absence of polymorphism. They
comprised MSP3.1 AA184–251, MSP3.2 AA161–257, MSP3.3
AA228–307, MSP3.4 AA508–579, MSP3.7 AA214–285, and MSP3.8
AA537–624. PP1 contains all the members of the MSP3 family. PP2
containing MSP3-1, -2, -4 and -7 was chosen to assess the effect of
sequences forming coiled-coil alpha helices inserted between the
MSP3 domains on its production and immunogenicity. Therefore,
peptide p27 described above was inserted in PP3, whereas PP4
containedacombinationofthemostcommontetrapeptiderepeated
units in the LSA3 AA223–586 region [15] (PlasmoDB ID:
PFB0915w). PP5 contains MSP3-1, -2, -3 and -8, PP6 contains
MSP3-1, -2 and -3 and PP7, MSP3-1 and -2. The last construction
(PP8) corresponds to a shortened version of MSP3.2-CT where an
embedded glutamic acid-rich region was deleted by linking the
sequences coding for AA161–257 to AA293–371.
Production of the recombinant proteins in Escherichia
coli
The immunogens used for the vaccination and antigens used in
the in vitro tests were produced in the BL21 strain of E. coli
Multivalent MSP3 Vaccines
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to a steady state phase and diluted 20-fold in fresh culture media.
The production of the recombinant proteins was induced with
IPTG (10 mM) when the bacteria culture reached an optical
density at 600 nm of 0.6. The bacteria were recovered after two
hours and a half of production in 25 ml of a lysis buffer (LB)
composed of 6M urea, 300 mM NaCl, 46.6 mM Na2HPO4,
3.4 mM NaH2PO4, and 10 mM imidazole and then lysed on ice
by ten one minute-long sonication pulses spaced by one minute
resting time. The lysate was cleared of debris by centrifugation
(10 000 g, 10 min, 4uC) and the supernatant passed through a
0.45 mm filter unit (Millipore). The recombinant proteins were
purified by affinity on 5 ml of a nickel-charged resin (Qiagen).
After washing the column with 10 ml of LB followed by two
washes with LB containing 20 mM of imidazole, the recombinant
proteins were eluted in 10 ml of LB with 250 mM of imidazole.
The eluted proteins were placed in membrane tubing with an
8 kDa of molecular weight cut-off (Spectrum Laboratories) and
dialyzed against 5 liters of phosphate buffered saline (PBS)
overnight at 4uC. The protein solutions were concentrated by
ultra filtration on membranes with a 10 kDa cut-off (Sartorius) and
passed through 1 ml of endotoxin removal resin with immobilized
polymixin B (Pierce). The endotoxin level in the protein
preparations was assessed with the PyroGeneH kit (Lonza)
according to the manufacturer instructions. Solutions negative
for the assay (sensitivity of 0,01 EU of endotoxin per ml) were
considered free of endotoxins. The protein concentration was
measured by the Bradford method (Bio-Rad) against a dilution
range of bovine serum albumin and adjusted to 1 mg/ml with
endotoxin-free PBS. They were stored at 220uC until use.
Mice and immunization protocol
Two inbred strains, C57BL/6 (H-2b) and BALB/c (H-2d) and
one outbred strain (Swiss), of four-week-old female mice were
obtained from Elevage Janvier (Le Genest-Saint-Isle, France). For
each mouse strain, the animals grouped by PP immunogen (n=7)
received every two weeks three immunizations and sera were
collected after the second and the third. In view of the deleterious
effect of repeated immunizations observed previously using the
MSP3.1 C-terminus construct, which was not observed using the
MSP3-LSP, all mice received thereafter three additional immu-
nizations to analyze effects of cumulative immunizations [13]. All
successive immunizations were performed by subcutaneous
injection of 20 mg of recombinant PP emulsified in 70%
Montanide ISA720 (Seppic, France) in a volume of 100 ml.
Control groups received adjuvant alone or the pre-erythrocytic
stage antigen, LSA1. Immune sera were collected from tail blood
two weeks post injection from the second and up to the sixth
injection and stored at 220uC until tested.
Western blotting
Proteins from 6610
7 schizont-infected erythrocytes were
separated by electrophoresis in a denaturing 10% polyacrylamide
gel and electro transferred on a nitrocellulose membrane
(Amersham Biosciences). After saturation in PBS-5% skimmed
milk (diluent buffer), membrane strips were cut and incubated for
one hour at room temperature on a rocking tray with pool of
immune sera from each immunization group tested at a 1:1000 in
diluent buffer. Strips were incubated for one hour with the
secondary antibody, a goat anti-mouse IgG conjugated with
alkaline phosphatase at 1:7500 in diluent buffer, and then
incubated in BCIP/NBT color substrate solution (both from
Promega). Uninfected erythrocytes and sera from adjuvant alone
immunized mice were used as negative controls.
Malaria-exposed individuals from Ndiop village
Antigenicity of each PP construct was assessed with sera
sampled from individuals living in Ndiop village (Senegal, West
Africa), a malaria mesoendemic area, described elsewhere [17].
Sera from individuals living in Ndiop, where obtained after using
stringent protocols of clinical follow-up consisting of daily
surveillance by a medical staff (present 24 hours a day, seven
days a week) in order to identify and to analyse each single episode
of morbidity [18,19]. The villagers received between 10 and 60
Figure 1. Diagrammatic representation of the MSP3-based PPs. The antigens in the PP constructs are colour-coded as follow; MSP3-1 (AA
184 to 251) in red, MSP3-2 (AA 161 to 257) in light green, MSP3-3 (AA 228 to 307) in orange, MSP3-4 (AA 508 to 579) in dark brown, MSP3-7 (AA 214
to 285) in dark blue, MSP3-8 (AA 537 to 624) in dark green. The construction PP8 is constituted by the assembly of the amino acid sequences 161–257
to 293–371 of MSP3-2. The amino acid sequences in the PPs correspond to the sequences of the clone 3D7 of P. falciparum. PP3 and PP4 contain p27
and LSA3 linkers respectively and are quoted in black on the diagram. The histidine tag appears in gray at the C-terminal extremity. The poly-bcd
polyprotein construct designed previously [13] which incorporates all the ‘‘b–d’’ regions of the six MSP3-CT antigens is also shown, for comparison.
The size and theoretical molecular weight of the polyproteins produced in E. coli are indicated.
doi:10.1371/journal.pone.0028165.g001
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11 years of age, 2 or 3 episodes of clinical malaria were detected
each year. A thick blood smear was Giemsa-stained and
examined immediately for the purpose of treatment when a
report or complaint of fever, headache or vomiting, were
observed by a trained nurse residing permanently in the village.
Irrespective of age, a parasite density threshold corresponding to
a trophozoite to leukocyte ratio above 0.5, i.e. roughly, a
circulating blood parasitaemia level of slightly less than 0.1%, or
5000 parasites/ml of blood, associated with clinical signs of
sickness was considered as a malaria attack. This diagnostic was
confirmed when the episode of illness disappeared after
appropriate anti-malaria treatment. The percentage of time
really spent in the village by the inhabitants tested in the present
study was 88.5% during the first year and 78.3% during the
entire clinical follow-up. Malaria attacks were detected in 64.3%
of the individuals who experienced a mean number of 2.6161.79
episodes during the first year of follow-up and 5.3963.74 clinical
attacks during the entire survey.
The informed consent of each villager (or that of the parents in
the case of children) was obtained at the beginning of the study
and was renewed at the beginning of each year of the survey. The
study design received clearance from the national Senegalese
ethical committee.
Enzyme Linked Immunosorbent Assay (ELISA)
Antibody responses against the six MSP3-CT peptides (i.e.
MSP3.1; MSP3.2; MSP3.3; MSP3.4; MSP3.7; MSP3.8) were
determined after each immunization with the PP constructs in
ELISA assays as described elsewhere [20]. 96-well polystyrene
plates (Costar) were coated overnight at 4uC with each MSP3-CT
peptide at 2.5 mg/ml in PBS. After saturation, plates were
incubated with mice immune sera in PBSM-0.05% Tween 20
(diluent buffer) at a 1:1000 dilution. This dilution was used
because it allowed comparison of antibody responses of the present
generation of MSP3-derived constructs with the previous one [13].
IgG and IgM antibody responses were revealed with a horseradish
peroxidase-conjugated goat-anti-mouse secondary antibody
(GAM-HRP) (Caltag Labs, Invitrogen) in diluent buffer at
1:3000 and 1:2000 dilutions, respectively. In addition, murine
IgG subclasses were measured with isotype-specific GAM-HRP
secondary antibodies diluted 1:4000 (IgG1, IgG2a, IgG2b), 1:2000
(IgG3) (Caltag Labs, Invitrogen) and 1:4000 (IgG2c) (Beckman
Coulter) in diluent buffer. The colorimetric reaction was triggered
by the adjunction of a TMB substrate solution (Uptima, Interchim)
and stopped with 1 M H3PO4 before reading of the optical density
at 450 nm (OD450). Determination of IgG titers in murine sera
was done from ten fold serial dilution (starting to 1:1000). A mean
OD450 value=0.2 was the end point titer considered for IgG titer
determination. For other murine data, the results were expressed
as the geometric mean of the OD450 obtained with single dilution
at 1:1000 of murine sera. The murine and human cytophilicity
ratios (CR) were calculated according to the following formulas;
((IgG2a+IgG2b+IgG2c)/(IgG1+IgG3+IgM)) and ((IgG1+IgG3)/
(IgG2+IgG4+IgM)), respectively. The CR value was considered
positive if .1, meaning thereby an isotypic imbalance in favour of
cytophilic IgG subclasses.
Briefly, the total IgG, IgM, and the IgG subclasses levels were
assessed in 1:100 diluted sera as described elsewhere [20]. Results
were expressed as OD450 ratios, which were calculated by dividing
the mean OD450 of test sera by the mean OD450 value+three
standard deviations of the mean obtained from healthy donors. A
serum was considered positive if this ratio was higher than 1.
Immunofluorescence assay (IFA)
The ability of mice immune sera to recognize native parasite
proteins on air-dried and acetone fixed thin smears of the blood
stage of P. falciparum (3D7 clone) was assessed by IFA as previously
described [21]. IFA and ADCI assays were performed the same
day, in order to check the antibody content of the sera after frozen
storage, and immediately before the functional assay.
Preparation of human blood monocytes
Peripheral blood mononuclear cells (PBMC) from healthy blood
donors were separated by Ficoll-Hypaque (P.A.A. GmBH,
Germany) density gradient centrifugation, washed in Ca
2+ and
Mg
2+ free HBSS buffered with 10 mM HEPES (Invitrogen). Cells
were frozen in heat-inactivated AB
+ human serum with 10%
DMSO (Sigma-Aldrich) at a final concentration of 15610
6 cells/
ml and stored in liquid nitrogen until use. The phenotype of the
monocyte (MN) sub-population was monitored by flow cytometry.
Briefly, 10
6 cells were incubated in 100 ml of PBS-5% FCS (FACS
buffer) in the presence of 0.1 mg/ml of anti-CD14-PE and anti-
CD16-PC5 (Beckman Coulter) for 30 min at 4uC in the dark. At
least 5.10
4 cells were acquired and then analyzed by flow
cytometry (FACSCalibur, BD Biosciences).
Antibody-dependent cellular inhibition assay (ADCI)
The ADCI assay previously described elsewhere [22,23] was
carried out with serial dilutions (2.5% - 0.5% - 0.1%) of pooled
sera from each PP-immunized mice groups corresponding
respectively to 1:200, 1:40, and 1:8 dilutions of the IFA final
antibody titre. A pool of sera from 180 hyperimmune African
adults (PIAG) was employed at 10% final (which corresponds to a
concentration of 2 mg/ml) as a positive control to assess the
reproducibility between each assay. A number of PBMC
containing 2.10
5 MN, according to flow cytometry phenotype
analysis, was added per well of a 96-wells flat bottom sterile plate.
MN were further selected by adherence after incubation for one
hour at 37uC, in a 5% CO2 atmosphere. An asexual blood stage
parasite culture with very mature schizonts (0.5% parasitemia,
2.5% haematocrit) was added on the MN monolayer previously
prepared. Murine test and control pooled sera were added
according to the serial dilutions described above. The intrinsic
anti-parasitic effect of the sera (control and test sera) was assessed
in wells containing the blood stages parasites without MN. Plates
were incubated in a candle jar at 37uC, in a 5% CO2 incubator. At
48 and 72 hours, 50 ml of CM was added to each well. At
96 hours the assay was stopped and the parasitemia determined by
flow cytometry (FACSCalibur, BD Biosciences).
Flow cytometry
The enumeration of erythrocytes infected by viable malaria
parasites was done by flow cytometry through a double staining
method using hydroethidine (HE) and thiazole orange (TO)
(Sigma-Aldrich) [24]. Briefly erythrocytes were incubated for
20 min at 37uC in the dark with 20 mg/ml of HE diluted in PBS-
1% FCS (FACS buffer), washed three times in FACS buffer,
followed by a 30 min incubation at room temperature in the dark
with TO diluted at 1:15000 in FACS buffer. Analyses were
performed on 1.10
5 erythrocytes with the CellQuest ProH
software. The parasitemia was determined as the percentage of
double stained infected erythrocytes among the whole erythrocyte
population. The specific growth inhibitory index (SGI) was
calculated according to the following formula: SGI=1006[12
(percent parasitemia with MN and mice test sera/percent
parasitemia with mice test sera)/(percent parasitemia with MN
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Based on results previously obtained with a range of negative and
positive controls (unpublished results), the threshold of positivity in
ADCI is .30% SGI. To take into account experimental variations
results are reported as Adjusted-SGI relative to the positive
reference control employed in each ADCI plate.
Statistical analysis
Results were tested in univariate analyses performed with the
Mann-Whitney U test. Available information pertaining to the
IgG isotype responses specific for the different polyproteins was
also analyzed in multivariate models. The potential association
between anti-MSP3 cytophilic responses (i.e. cytophilicity ratios)
and the occurrence of malaria attacks was tested with the JMPH
software (SAS Institute). We applied a stepwise regression model
in which the effect of age and that of all other confounding
variables suspected of having a potential impact on the
occurrence of malaria attacks was included (Hb phenotype,
G6PD deficiency and the time actually spent in the village). The
explanatory variables tested were selected because of our existing
knowledge of the potential involvement of these different
parameters (with reference to published papers and to our
previous observations in different malaria endemic areas). The
relationship between the variable to explain (the number of
clinical episodes of malaria) and the available explanatory
variables was tested and the variables that were identified as
non-significant were eliminated. The criterion for elimination was
that a predictor variable was excluded when its partial regression
coefficient failed to be significant at the 0.1 level. The F ratio was
the test statistic used to determine whether the model as a whole
had statistically significant predictive capability in the regression
framework. Departures from the null hypothesis tended to give
values of F ratios that were greater than unity. The null
hypothesis was rejected when the F ratio was large and the
associated p values were low. Since we used at least eight
successive tests (one per construct) to look for the possible
association between antibody responses and the number of
malaria attacks identified over one and three years periods after
the blood sampling, we decided to consider a value of p,0.0031
as significant (Bonferroni correction).
Results
Production of PPs in E. coli
The eight chimerical PPs were readily produced in E. coli with
similar yields ranging from three to five milligrams per litre of
culture. The recombinant products that were purified by affinity
chromatography showed the expected experimental molecular
weights for polypeptides ranging from 178 to 489 amino acids
without detectable degradation products (Figure S1A). The
immunological specificity of the recombinant PPs was confirmed
by western blotting with an anti-MSP3.1 rat immune serum
(Figure S1B).
PPs are immunogenic and induce cross-reactive
antibodies against the proteins from the MSP3 family
The magnitude and kinetics of the antibody responses induced
by the PP constructs mounted against each MSP3-CT antigen
were assessed in three mouse strains (C57BL/6, BALB/c and
Swiss). Results show that the IgG responses against most of the
antigens reach a maximum after two immunizations independent
of both the immunogen employed, and the genetic background of
mice, suggesting a minimal implication of the host genetic
background on the induction of the antibody response against
the MSP3-CT proteins (Figure 2). Responses to other antigens
from the MSP3-CT family, not included in the immunogens,
developed later, such as for example against MSP3.8-CT in
animals immunized with the MSP3.1247-based constructions
(PP2, PP3 and PP4), where the response reached a plateau after
three to five injections. These delayed responses may reflect a
qualitative change over time - a maturation of immune responses -
which progressively extends to cross-reactive epitopes not included
in the PPs.
The addition of repeated motifs from LSA3 and p27 forming
coiled-coil alpha helices that are unrelated to MSP3 between the
members of MSP3.1247 (PP3 and PP4) did not lead to any
detectable change in the profile of the immune response,
suggesting that they do not contribute to modify the immunoge-
nicity of the MSP3 antigens as compared to PP2. Mice that
received controls immunogens such as adjuvant alone or an
irrelevant antigen (LSA1) did not develop any detectable specific
anti-MSP3 response. Finally, over-immunization by delivering 3
boosting doses after the third immunization did not result in any
significant decrease in antibody titers related to the induction of
possible immune-regulatory mechanisms, as had been observed
using MSP3.1-CT [13]. Antibody titers observed with the present
PP constructs, against MSP3-CT antigens after the third
immunization, were higher and more homogenous (Figure 3)
than titers obtained when using the preceding generation of PP
construct that was made by combining domain covering the ‘‘b–d’’
region from each MSP3-CT antigen extensively described
elsewhere [11,12,13].
Murine cytophilic IgG are predominant subclasses after
immunization with PPs
A correlation between the progressive acquisition with age of
cytophilic antibody isotypes directed against P. falciparum specific
antigens (such as the members of the MSP3 family) and
protection against clinical malaria had been identified in several
immuno-epidemiological studies [10,25,26]. We evaluated the
potential of the newly designed PPs to induce such isotype
imbalanced responses in sera of immunized mice by measuring
the cytophilicity ratio (CR). The cytophilic response against all
MSP3-CT antigens was predominantly of the IgG2a isotype in
BALB/c and Swiss strains (Figure S2), whereas the IgG2c
isotype was predominant in the C57BL/6 strain (Figure S3).
Indeed, it has been established that mice with a B6 genetic
background preferentially express antibodies of the cytophilic
IgG2c isotype instead of the IgG2a [27,28,29,30]. Further
support for the preceding statement is evident from the fact that,
specific IgG2b response against each MSP3-CT antigen was
similar in these three murine distinct genotypes. Among the non
cytophilic responses produced, the IgG1 isotype prevailed over
the IgG3 and IgM subclasses in the three strains of mice (data
not shown). In agreement with these results, CR were
comparable with few exceptions, whatever the immunogen
and the MSP3-CT antigen analyzed. Values of CR were
generally greater than one in the inbred C57BL/6 and BALB/c
(respectively, Figure 4A and 4B) and in outbred Swiss
(Figure 4C) mice. Some PPs resulted in particularly high CR
(CR.3) as for example, antibodies induced by PP3 against
MSP3.3-CT in BALB/c (Figure 4B), or antibodies induced by
PP2 against MSP3.4-CT, or those induced by PP3 against
MSP3.1-CT, or by PP3, PP4 and PP5 against MSP3.8-CT in
Swiss mice (Figure 4C). Altogether, these results confirm the
potential of these constructs to generate a network of cross-
reactive functional cytophilic antibodies against all the members
of the MSP3 family in diverse mouse genetic backgrounds,
Multivalent MSP3 Vaccines
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to malaria [12]. There is a clear improvement in the quality of
the humoral response induced against MSP3 antigens by the
newly designed PPs, as compared to the first multigenic
construct ‘‘poly-bcd’’ previously studied [13], when using the
same adjuvant in the same mice strains.
Antigenicity studies show a dominance of cytophilic IgG
in sera of malaria-exposed individuals
We analyzed the reactivity with each PP of naturally acquired
IgG present in the sera from a small cohort of malaria-exposed
individuals (n=28, mean age=18610.5 years). All the sera from
villagers tested recognized each PP, and this recognition was
Figure 2. Time course of specific PP-induced IgG against MSP3-CT antigens. Kinetic of immunogenicity of PPs against each of the MSP3-CT
antigen was investigated in mice of three distinct genotypes. Total IgG response was measured every two weeks after each immunization and
expressed as mean OD450 value. The arrows on the x-axis indicate the timing of the subcutaneous injections of 20 mg of recombinant PPs in
Montanide ISA720 adjuvant. In the particular case of MSP3-1 values are only indicative as they are higher than OD=5, i.e. than the linear range of the
reader.
doi:10.1371/journal.pone.0028165.g002
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(Figure 5A). Importantly, these responses were higher in compar-
ison to the MSP3-LSP ninety-six residues long peptide (MSP3.1
aa154–249) currently assessed in clinical trials [5,7,8,9]. We observed
that all PPs were mainly targeted by human cytophilic IgG1 and
IgG3 antibodies with a high CR ranging from 2 for PP4, up to 8 for
PP2 (Figure 5B). In addition, antibody response with a higher CR
than MSP3-LSP targeted PP1, PP2, PP6 and PP8. Surprisingly the
tetravalent construct, PP2, stands out as the most valuable, i.e. more
than the hexavalent construct, PP1, in this respect.
We then analyzed the potential relationship between this
natural antibody response and the occurrence of malaria attacks
recorded over a period of one and three years, during which the
mean number of attacks was 1.6861.91 and 3.4663.91
respectively. We first performed an univariate analysis showing
an association between high cytophilic responses against MSP3-
LSP and low number of malaria attacks over a one year period
(R
2=0.208, p=0.0147), which remained statistically significant
over three years of follow-up (R
2=0.241, p=0.0079). Immune
responses against PP1, PP7 and PP8 showed the same
association with protection from malaria attacks (R
2=0.281,
0.223, 0.284, respectively) as that observed with MSP3-LSP,
over a one year period, without increase in significance over
three-years of follow-up. Conversely, high CR values did not all
Figure 3. Immunogenicity of the PPs against MSP3-CT antigens. Total IgG titers were measured two weeks after the third immunization of
C5BL/6 (A), BALB/c (B) and Swiss (C) with MSP3 polyprotein constructs. IgG titers for LSA1 or adjuvant immunized mice, not represented here, against
MSP3 family antigens were insignificant. End point for IgG titer determination was a mean OD450=0.2.
doi:10.1371/journal.pone.0028165.g003
Multivalent MSP3 Vaccines
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28165correlate with a lower occurrence of malaria attacks, as in
contrast no significant association was found for instance with
PP2 (R
2=0.097). Models of interactions between malaria attacks
and available explanatory variables were then tested by
multivariate analyses taking into account antibody response
levels, age, G6PD deficiency, Hb phenotype and the proportion
of time spent in the village during active follow-up. Models of
interactions show that the strongest association is found between
high anti-MSP3-LSP cytophilic responses and a limited number
of malaria attacks over one and three yeas of follow-up
(R
2=0.498, p,0.0001 and R
2=0.569, p,0.0001, respectively).
An association between high anti-MSP3-LSP cytophilic respons-
es and the occurrence of a limited number of malaria attacks,
was found and increased from one to three years of follow-up
(with F=4.99, power analysis=0.575; p=0.03347 and F=6.91,
power=0.715; p=0.01444, respectively). Among the PP con-
structs, the model of interactions showed the best fit between
high anti-PP8 cytophilic antibody responses and low number of
malaria attacks during one year of follow-up (R
2=0.499
p,0.0001). Similarly, specific PP8 cytophilic antibody was
associated with reduced malaria attacks experience during the
first year of follow-up (F=5.02; power=0.577; p=0.0342). Other
results to other constructs show the same trend though several do
not reach significance most likely due to the small size of the
cohort studied.
PP-induced antibodies react with native parasite
antigens
Immunofluorescence (IFA) and Western blotting were used to
analyze the ability of PP-induced antibodies to recognize
epitopes expressed by native proteins on asexual blood stage
parasites. IFA results showed that all PP-induced antibodies in
the three mouse strains after the third immunization recognized
epitopes on native proteins of P. falciparum parasites with titers of
up to 1:8000. Sera from mice immunized with adjuvant alone or
LSA1, an antigen exclusively expressed during the parasite liver
stages, were unable to recognize parasite asexual blood stages
(Figure S4). The specificity of the antibody response was further
characterized by western blotting where IgG from immune sera
sampled two weeks after the third immunization with PPs
showed a strong reactivity with MSP3 proteins (Figure 6A). Such
specific IgG binding was mostly directed against two proteins
corresponding to MSP3.1 at 48 kDa and MSP3.2 at 36 kDa,
and this was confirmed by competition experiments carried out
with the corresponding soluble recombinant MSP3 peptides,
respectively (data not shown). The specificity to the other
discrete MSP3 bands could not be assigned to a particular MSP3
antigen. PP3 and PP4 induced antibodies specific for the p27
and LSA3 peptides, respectively. No antigen recognition was
detectable with sera from mice immunized with adjuvant alone
or LSA1.
The PPs induced a long-lasting anti-MSP3 response, detectable
six months after the last injection, and antibody reactivity was
almost entirely directed against MSP3.2, pointing to this MSP3
family member as one with unique features (Figure 6B). Immune
sera from outbred Swiss mice were the most reactive against the
native MSP3 antigens, particularly during the memory phase of
the response. PP8 stands out by eliciting a markedly stronger
antibody response against the native MSP3.2 antigen, as seen in
sera from BALB/c and Swiss strains collected six months after the
last immunization. The reasons for this observation are not clear,
Figure 4. PPs induce a dominance of murine cytophilic IgG
against MSP3-CT antigens. Cytophilicity ratio (CR) of IgG response
against MSP3-CT antigens was assessed in C57BL/6 (A), BALB/c (B) and
Swiss (C) mice, two weeks after the third immunization with PPs. CR was
measured as following (IgG2a+IgG2b+IgG2c)/(IgG3+IgG1+IgM). Results
were expressed as the geometric mean of the OD450 obtained for the
single dilution of sera at 1:1000.
doi:10.1371/journal.pone.0028165.g004
Figure 5. Antigenicity of the PPs with sera from malaria-
exposed individuals. (A) Analysis of the antibody isotype responses
against the PPs. Results are expressed as mean OD450 values. (B)
Determination of the cytophilicity ratio (IgG1+IgG3/IgG2+IgG4+IgM)
associated to the antibody response to each PP.
doi:10.1371/journal.pone.0028165.g005
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responses.
PP-elicited antibodies inhibit in vitro growth of
P. falciparum in ADCI assay
In vitro inhibition of asexual blood stage parasites by PP-induced
antibodies was assessed in ADCI assay using sera collected after
the third immunization for some mice strains (Figure S5) and after
the fifth injection for all strains (Figure 7). As negative control, we
used LSA1, a liver stage antigen eliciting also a majority of
cytophilic antibodies but having no significant ADCI activity. In
addition, no significant direct inhibitory effect (,15% parasitic
growth inhibition) of parasite growth by antibodies alone was
observed. The observed anti-parasitic activity in monocyte-
dependant fashion was strong and homogeneous using sera from
all PP-immunized groups from the three strains of mice already
after the third and later after the fifth immunization. The
inhibitory effect of induced antibodies was as high as, or higher
than, that obtained using the pool of African immunoglobulins
(PIAG) even though mice sera were assessed at a four-fold lower
concentration (2.5%) than the PIAG (10%). This PP-specific anti-
parasite activity remained substantial when sera were used at 0.5%
concentration (diluted 200 fold) but decreased notably at 0.1%. No
significant ADCI effect was observed with sera from mice
immunized by LSA1 or by the adjuvant alone. As a further
example of the potency of the antibodies elicited by the constructs,
the ADCI activity was similar using the PP-immunized mice sera
at a 10 fold lower concentration than affinity purified human anti-
MSP3.1b IgG [6].
Discussion
We report here the design and analysis of the immunological
properties of eight PPs combining one or several peptides
belonging to the MSP3 family of proteins. The reactivity pattern
of these new vaccine constructs showed that: a) they induced, in
genetically distinct mice, antibodies that recognize P. falciparum
antigens and native parasite proteins from asexual blood stage with
a marked prevalence of cytophilic IgG subclasses; b) they favoured
the induction of cross-reactive antibodies targeting the structurally
related MSP3 epitopes; c) they all bound natural IgG from sera of
malaria-exposed people with a predominance of specific cytophilic
IgG subclasses; d) PP-induced antibodies exerted a strong
Figure 6. PP-elicited IgG recognize native proteins of the asexual blood stage P. falciparum. Western blotting of human erythrocytes
infected by Plasmodium falciparum (3D7 clone) and probed with pooled immune sera from groups of mice two weeks (A) or six months (B) after the
sixth immunization with polyproteins or with adjuvant alone (mock immunized).
doi:10.1371/journal.pone.0028165.g006
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than that obtained with the first MSP3-LSP construct designed.
Our interest for this multigene family and for vaccine
constructs deriving from its different members originates from
the protection elicited in African children by MSP3.1 [9], and
from the very unusual features of this multigene family [11]. The
six C-terminal regions are all expressed by each parasite, have a
very similar organisation, are all remarkably conserved in
different falciparum strains and they are targeted by broadly cross
reactive cytophilic antibodies effective in the MN-dependant
ADCI mechanism. Given these features, it was considered logical
to produce vaccine constructs by assembling the most represen-
tative regions from the C-term of those genes under the main
hypothesis that vaccines generating the same wide range of
diverse antibody species should contribute to improved biological
anti-parasite activity.
Vaccine constructs targeting different antigens at different stages
of the parasite cycle are considered as attractive combinations in
view of both the great genetic variability and complexity of the
parasite life cycle, illustrated by the extensive repertoire of various
proteins expressed by blood schizonts [31]. The development of an
effective multi-epitopic malaria vaccine is currently under
investigation by different research groups with promising results
displayed in animal models. Several of these studies usually
associate either two distinct antigens from two different stages of
the life cycle, or two different antigens from the same stage. This is
a markedly different approach as compared to ours, as each of the
epitopes selected in our multigene constructs was chosen based on
detailed analyses [1,6,10,12,13] exclusively relying on indications
originating from natural interactions between human hosts and
falciparum parasites, and also because the constructs contained
antigens from structurally related genes [2,11].
Figure 7. PP-induced antibodies inhibit in vitro the growth of the asexual blood stage of P. falciparum in ADCI. ADCI was performed
with human MN and parasites cultured for 4 days with immune sera from C57BL/6 (A), BALB/c (B) and Swiss (C) mice harvested two weeks after the
fifth immunization with the MSP3-PPs. Sera from mice immunized with an irrelevant P. falciparum antigen (LSA1) or with the adjuvant alone, were
used as negative controls. A pool of immune sera from individuals living in endemic areas (PIAG) was used as positive control. The PIAG was used at a
dilution of 10%, the mice immune sera were used at a 5-fold serial dilution of 2.5%, 0.5% and 0.1%. Results are expressed as adjusted SGI values
compared to the PIAG value that was redressed to 100% of SGI effect.
doi:10.1371/journal.pone.0028165.g007
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and T-helper cells to a repertoire of epitopes from a single gene
family showing epitope redundancy. Hence, the goal was to
improve immune responses towards similar targets and not to
combine immune responses to different target antigens. The
resulting value of the constructs was analyzed at the pre-clinical
level in experimental rodent models. Whereas a first vaccine
candidate has already gone far in its clinical development, the goal
of our approach was to develop a second generation of MSP3-
derived vaccine with improved features.
The present eight PPs designed to increase the number of ADCI
targets were easily expressed in Escherichia coli, and purified as
soluble recombinant proteins retaining their antigenicity. Both
immunogenicity and antigenicity data indicate that the critical
epitopes contained in PPs have not been altered by the
construction, are accessible to antibodies, and stimulate the
desired subclasses of antibodies.
Immunogenicity was the first criterion to satisfy. Immuniza-
tions of three genetically distinct mouse strains with the PPs
induced high and long lasting humoral response against MSP3
antigens. This specific response was induced rapidly, usually after
a single immunization with peak intensity generally observed
after the third immunization. Immunogenicity data in three
rodent species used herein, showed no evidence for major genetic
restriction, i.e. overall homogeneous responses with relatively
minor differences.
The second important criterion, induction of antibodies with a
dominance of cytophilic IgG subclasses, was also fully satisfied.
Though there were understandably a range of CR values from one
construct to the other, in diverse breeds of mice, and in malaria
exposed humans, the important point is that in all cases there was
a dominance of cytophilic humoral responses, as shown by a
CR.1. Our results demonstrate that a majority of murine
cytophilic IgG subclasses (namely, IgG2a, IgG2b and IgG2c) were
elicited after three immunizations as expressed by the cytophilicity
ratio values attesting of a favourable isotypic balance. Indeed for a
mechanism such as ADCI which implies a triggering of monocytes
trough their Fc-c receptors, the ‘‘quality’’ of the antibody response
directed against the members of the MSP3 family is an important
criterion. This may indirectly indicate that the constructs included
T-helper cell epitopes effective in diverse genetic backgrounds.
The prevalence of cytophilic IgG subclasses, i.e. able to bind to Fc-
c receptors expressed at the surface of monocytes is in keeping
with the induction of a Th-1 response as was already reported for
the first multigenic construct which induced high levels of IFN-c
[13]. Other reports have shown that immune responses skewed
toward a Th1-like response are involved in the production of
murine IgG subclasses, notably IgG2a [32,33,34]. Incidentally,
our results also stress the importance of investigating the IgG2c
isotype, particularly in C57BL/6 mice, by using secondary
antibodies that are specific for this rather unusual IgG subclass.
A third important goal reached was the generation of a broader
immune response directed at several, or nearly all, members of the
MSP3 protein family. Indeed, by combining a number of epitopes
belonging to the same family of proteins, we could extend the
reactivity of elicited antibodies to other related epitopes, not
contained in the immunogens. This observation proved true for
the majority of the six MSP3 antigens in two out of the three
genetically distinct mice tested. However, in the majority of cases,
by combining selected epitopes originating from the antigenic
motifs of a conserved protein family, it proved possible to induce
high levels of cross-reactive antibodies targeting several well-
conserved epitopes including both those with sequence identity
and those with sequence divergences.
The last goal reached was to induce antibodies with a
satisfactory functional activity in vitro against asexual blood stage
parasites of P. falciparum. ADCI assays demonstrated the ability of
PP–elicited antibodies to react with native parasite antigens and to
cooperate with MN to achieve parasite killing. Importantly this
antiparasitic activity was observed for antibodies induced by all of
the constructs. No enhancement was observed. Furthermore, anti-
PPs antibodies exhibited a strong effect, similar or higher than that
obtained using the PIAG, i.e. the pool of sera which following
passive transfer reduced parasitaemia in malaria patients [35]. The
growth inhibition effect remained significant even at low
concentration i.e. when sera were diluted 200 fold. It is worth
noting here that the capacity to inhibit in vitro the growth of P.
falciparum asexual blood stages using the ADCI assay was stronger
than that found with the antibodies produced by the vaccine
candidate MSP3-LSP. The specific parasite growth inhibition
associated with sera from mice immunized with the PP8 was the
highest, remaining quite significant even with sera diluted 1,000
fold (i.e. diluted one hundred-time more than the PIAG). This last
observation is in agreement with a previous study reporting the
value of MSP3.2 as vaccine candidate [36].
Antigenicity studies with sera from endemic area populations
bring support to the relevance of mouse data to the human
situation. Indeed, naturally occurring IgG recognized the various
constructs with predominance of cytophilic antibodies. Further-
more, in these sera, reactivities observed against the PPs displayed
similar or higher prevalence and IgG response than against the
individual epitopes [12].
Over-immunization by giving three additional injections after
the first three, i.e. six in total, was used as a mean to investigate the
possibility that immunoregulatory regions were included in the
constructs. Indeed, using the whole C-term region of MSP3.1 we
observed previously that over immunization induced a sharp
decrease in antibody titers as compared to those obtained after
three immunizations, particularly in C57BL/6 mice [13]. This
effect was found related to the inclusion of the ‘‘e–f’’ peptide
region in the immunogen. Although, no attempt was made to
characterize the nature of this regulatory mechanism nor to
identify the epitopes involved in this effect within those regions,
this observation nevertheless led us to choose the MSP3-LSP in
which the extreme C–term region (covering peptides ‘‘e’’ and ‘‘f’’)
prone to induce a down regulation of immune responses is
excluded. Results from mice receiving six consecutive immuniza-
tions of our constructs, did not show any decrease in antibody
responses, with any of the constructs studied, indicating they are
not prone to induce the regulatory effect previously observed with
MSP3-1 C-term region. Results show that using a similar
immunization protocol, i.e. with the same adjuvant and in the
same mouse strains, the new vaccine constructs induced antibody
responses similar in three different mouse genetic backgrounds,
and higher titers as compared to what was found using the first
generation, MSP3-LSP as well as the first MSP3-derived
multigene construct [13].
Hence, most constructs were effective, and nearly all satisfied
the criteria of immunogenicity, antigenicity, cytophilicity, and
antibody functional activity. However, this was, to a certain extent,
unexpected. In spite of their satisfactory features, the newly
designed PPs do not enable us to single out a particularly ‘‘better’’
vaccine construct from the group of eight, with superior features
compared to the others, to be taken forward into clinical
development.
Avidity studies did not distinguish either the antibodies elicited
by each PP. The avidity of antibodies elicited by the PPs was
indirectly evaluated in sera sampled after the third and the fifth
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P.falciparum, in the presence of increasing concentrations of the
chaotropic ion NH4SCN. Results (not shown) indicate that 50% of
the reactivity of PP specific IgG to native antigens was removed by
1 M and 1.5 M NH4SCN in sera taken after the third
immunization, and after the fifth immunization, respectively.
These results indicate relatively high avidities of PP-induced
antibodies, which increase with the number of immunization
stressing thereby the occurring immunologic selection in favour of
antibodies with better-fitted paratopes. Results were similar in
each of the three mice strains (not shown). Thus, the IgGs induced
by each of the eight PPs displayed similar patterns of avidity in the
assay employed.
The addition of coiled-coil fragments from different proteins
had no significant effect. These were added with two goals. The
first one being to improve overall structure of MSP3 antigens, with
the implication that it may improve immunogenicity, the other
being to combine responses against MSP3 and against repeat
domains from other vaccine candidates (namely, antigens from
asexual liver and blood stages, LSA3 and p27 respectively).
Available results do not indicate that either of those hypotheses
was true. Responses to MSP3 antigens was as good as but not
better than without the additional antigens.
It is well known in the malaria vaccine development field that
mouse immune responses frequently differ from those of human
volunteers leading in phase I trials to an immunogenicity of
vaccine prototypes frequently different to that obtained in
preclinical models. Therefore, even if most vaccine constructs
satisfied the majority of our criteria in preclinical conditions, it
would be required to address the immunogenicity and particularly
the duration of functional immune response in a phase I trial
where two or three selected constructs would be investigated head
to head. Given the above results, our choice of candidate
molecules that should be taken forward to clinical trials, would
include two, if not three of the PPs selected based on the assays
reported herein. Based on the preclinical data and the clinical
results obtained with MSP3-LSP, it is anticipated that each of
those three should be immunogenic in humans as was seen across
three mouse strains. Criteria for such a phase Ia study would be
the titers, cytophilicity ratio and above all, duration of functional
immune responses in humans.
Supporting Information
Figure S1 Quality control of the production in E. coli of
the recombinant PPs. Electrophoresis of one microgram of the
purified PPs on a 10% acrylamid gel under denaturing conditions
and Coomassie blue staining (A). Western blotting of the PPs probed
with a rat anti-MSP3.1 immune serum at a 1:100 dilution (B).
(TIF)
Figure S2 Induction by PPs of specific IgG2a against
MSP3-CT antigens. Determination of specific murine cytophil-
ic IgG2c against the MSP3-CT antigens, two weeks after the third
injection of 20 mg of immunogens adjuvanted in Montanide
ISA720. Results were expressed as the geometric mean of the
OD450 obtained for the single dilution of sera at 1:1000.
(TIF)
Figure S3 Induction by PPs of specific IgG2b against
MSP3-CT antigens. Determination of specific murine cytophil-
ic IgG2a against the MSP3-CT antigens, two weeks after the third
injection of 20 mg of immunogens adjuvanted in Montanide ISA
720. Results were expressed as the geometric mean of the OD450
obtained for the single dilution of sera at 1:1000.
(TIF)
Figure S4 Binding of PP-induced IgG to native proteins
from asexual blood stages parasites of P. falciparum.
Immunofluorescence analysis with immune sera from BALB/c
mice immunized with adjuvant alone (upper left); PP1 (upper
right); PP8 (lower left) and LSA1 (lower right) collected after the
third immunization. Staining on acetone-fixed thin smear of very
mature stages asexual blood stages from P. falciparum (3D7 clone)
was made with murine immune serum used all at 1:1000 final
dilution.
(TIF)
Figure S5 Anti parasitic activity of PP-induced antibod-
ies in ADCI against P. falciparum asexual blood stage
parasites. In vitro growth inhibition of P. falciparum parasites (3D7
clone) cultured in presence of human monocytes and immune sera
from C57BL/6, BALB/c and Swiss mice harvested two weeks
after the third immunization with PPs. Sera from BALB/c mice
immunized with non relevant P. falciparum antigen (LSA1) and
with adjuvant alone, were used as negative controls. A pool of
immune sera from individuals living in endemic areas (PIAG) was
used as positive control. The PIAG was used at a dilution of 10%,
the mice immune sera were used at a serial dilution of 2.5%.
Results are expressed as adjusted SGI values compared to the
PIAG value that was redressed to 100% of SGI effect.
(TIF)
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